Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...

The litigation initiated by Rigel was a response to Annora’s submission of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA), seeking approval for a generic ...

Investing.com — Rigel Pharmaceuticals , Inc. (NASDAQ:RIGL)，一家在过去十二个月内实现了54.71%显著收入增长的制药公司，已与Annora Pharma Private Ltd.、Hetero Labs Ltd.和Hetero USA, Inc.（统称为Annora）就Rigel的TAVALISSE（fostamatinib disodiu ...

After hours: March 25 at 7:35:11 PM EDT Loading Chart for RIGL ...

The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non ...

The litigation initiated by Rigel was a response to Annora’s submission of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA), seeking approval for a generic version ..